Unick, J
Rajiv Roy Diabetes Medical Director Endocrinology Leads and oversees your care team
GLP-1 peptide molecules are simply too large to pass through the skin and enter the bloodstream through an adhesive patch, so even if a product claimed to contain real medication, the delivery method would not work
In practice, this changes procurement and oversight in several ways: Product positioning needs to be precise because labeling should stay within laboratory, analytical, or preclinical research use Vendor claims need scrutiny because promotional language can drift into drug-like implications that do not match the products status Study records need clear intent because the material should be tied to defined research activities rather than any human-use assumption Combination products deserve extra caution because a stack can look more developed than the evidence behind each component or the blend itself A simple screening question helps: if the seller describes a KLOW-style blend like an established treatment, the compliance risk rises immediately

and as a structural biology ligand, with cryo-EM structures of full-length MC4R in complex with heterotrimeric Gs resolving afamelanotide in the orthosteric pocket alongside alpha-MSH and describing a conserved binding mode for peptidic melanocortin agonists
The fees Henry does not charge There is no membership fee and no per-visit consultation charge